A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

The interim data from Pfizer and BioNTech showing 90% efficacy this week was at the same time a big step and a baby step for the field, according to Mene Pangalos, who sees a long to-do list for the industry on the pandemic.

Pangalos, EVP of biopharmaceuticals R&D at  AstraZeneca plc (LSE:AZN; NASDAQ:AZN), discussed his outlook for the pandemic in a BioCentury This Week – Special Edition audio interview recorded on Nov. 10...